Premium
Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
ANI Pharmaceuticals Completes Acquisition of Generic Products and Assets from Amneal/Impax PR Newswire BAUDETTE, Minn., May 7, 2018 BAUDETTE, Minn., May 7, 2018 /PRNewswire/ -- ANI...
Amneal and Impax Complete Business Combination ‒ Creates Diversified Pharmaceutical Company with 5th Largest Generics Business in the United States ‒ ‒ Combined First Quarter 2018 Total Revenues...
Apergy Set to Join S&P MidCap 400; 3D Systems to Join S&P SmallCap 600 PR Newswire NEW YORK, May 2, 2018 NEW YORK, May 2, 2018 /PRNewswire/ -- Apergy Corp. (NYSE: APY) will replace 3D...
Amneal And Impax Receive FTC Clearance For Business Combination PR Newswire BRIDGEWATER, N.J., April 27, 2018 BRIDGEWATER, N.J., April 27, 2018 /PRNewswire/ -- Amneal Pharmaceuticals LLC and...
ANI Pharmaceuticals Signs Definitive Agreements to Acquire Generic Products and Assets from Amneal/Impax PR Newswire BAUDETTE, Minn., April 27, 2018 BAUDETTE, Minn., April 27, 2018 /PRNewswire/...
Impax Launches a Generic Version of Estrace® Cream (estradiol vaginal cream, USP, 0.01%) PR Newswire BRIDGEWATER, N.J., April 6, 2018 BRIDGEWATER, N.J., April 6, 2018 /PRNewswire/ -- Impax...
Impax Shareholders Approve Proposed Business Combination with Amneal PR Newswire BRIDGEWATER, N.J., March 27, 2018 BRIDGEWATER, N.J., March 27, 2018 /PRNewswire/ -- Impax Laboratories, Inc...
Amneal Gains Approval for Erythromycin Tablets USP PR Newswire BRIDGEWATER, N.J., March 14, 2018 BRIDGEWATER, N.J., March 14, 2018 /PRNewswire/ -- Amneal Pharmaceuticals has received FDA approval...
Amneal Pharmaceuticals and Impax Laboratories to Present at the Barclays Global Healthcare Conference PR Newswire BRIDGEWATER, N.J., March 7, 2018 BRIDGEWATER, N.J., March 7, 2018 /PRNewswire/...
Amneal Launches Generic for Tamiflu® Oral Suspension PR Newswire BRIDGEWATER, N.J., March 1, 2018 BRIDGEWATER, N.J., March 1, 2018 /PRNewswire/ -- Amneal Pharmaceuticals has launched oseltamivir...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
